Clemidsogene lanparvovec (RGX-121) is an investigational, one-time intracisternal adeno-associated virus serotype 9 (AAV9) gene therapy delivering the iduronate-2-sulfatase (IDS) gene directly to...

Prior authorization using integrated medical claims data helps diabetes patients get medications faster, with two-thirds processed automatically by July 2025 in this Prime Therapeutics analysis

The information provided has been developed based on available information as of March 3, 2025. This therapy is NOT FDA approved, and content may change as more information becomes available....

Gene therapy harnesses the body’s capacity to heal itself

Prime Therapeutics Report shares more about single-treatment gene therapies and proper management

cover image for Summer 2025 Issue: Clinical Insights – MASH A new era in liver health: Treatment innovation, payer strategy, and pipeline momentum Prime Therapeutics...

publications Spring 2024 Prime Therapeutics Report March 15, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 6)...

References Abeona Therapeutics announces FDA accepts and grants Priority Review for Pz-cel biologics license application (BLA). November 27, 2023. Available at:...